Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines

British Journal of Clinical Pharmacology

Volumn 42, Issue 4, 1996, Pages 423-429

  Smith, C C ^a   Bennett, P M ^a   Pearce, H M ^b   Harrison, P I ^c   Reynolds, D J M ^d   Aronson, J K ^d   Grahame Smith, D G ^d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Oxford Regional Genetics Service   (United Kingdom)

^d RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

adverse drug reactions; Committee on Safety of Medicines; yellow cards

Indexed keywords

UNINDEXED DRUG;

ADVERSE DRUG REACTION; ARTICLE; DRUG SAFETY; HOSPITAL; HUMAN; PATIENT MONITORING; PHARMACIST; PHYSICIAN; PRIORITY JOURNAL; REGISTRATION;

EID: 0029799131     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00004.x     Document Type: Article

References (20)

1. Lawson DH. The yellow card: mark II. Br Med J 1990; 301: 1234.
2. Rawlins MD. Spontaneous reporting of adverse drug reactions. 1. The data. Br J Clin Pharmacol 1988; 26: 1-6.
3. Medicines Control Agency. Annual report and accounts 1993/94. London: HMSO, 1994: 4.
4. Lumley CE, Walker SR, Hall GC, Staunton N, Grob PR. The under-reporting of adverse reactions seen in general practice. Pharm Med 1986; 1: 205-12.
5. Griffin JP. Survey of spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 1986; 22: 83S-100S.
6. Booth NJ, Luscombe DH, Smith CC, Veitch GBA, Grahame-Smith DG. Scheme to promote, monitor and assess the reporting of adverse drug reactions. Pharm J 1988; 241: R3.
7. Booth NJ. The role of the hospital pharmacist in adverse drug reactions. MPhil Thesis, 1989, University of Wales College of Cardiff.
8. Smith CC, Bennett PM, Pearce HM, Reynolds DJM, Aronson JK, Grahame-Smith DG. NSAIDS and gut toxicity. Lancet 1994; 344: 56-7.
9. Committee on Safety of Medicines. Mianserin (Bolvidon, Norval) and blood dyscrasia. Curr Prob 1981; 7.
10. Committee on Safety of Medicines. Serious adverse reactions with amiodarone (Cordarone X). Curr Prob 1984; 13.
11. Committee on Safety of Medicines. Withdrawal of terodiline. Curr Prob 1991; 32.
12. Committee on Safety of Medicines. Advice about adverse drug reaction reporting. Curr Prob 1990; 30.
13. Hutchinson TA, Flegel KM, Ho Ping Kong H, Bloom WS, Kramer MS, Trummer EG. Reasons for disagreement in the standardized assessment of suspected adverse drug reactions. Clin Pharmacol Ther 1983; 34: 421-6.
14. Larmour I, Dolphin RG, Baxter H, Morrison S, Hooke DH, McGrath BP. A prospective study of hospital admissions due to drug reactions. Aust J Hosp Pharm 1991; 21: 90-5.
15. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832-40.
16. Winstanley PA, Irvin LE, Smith JC, Orme ML'E, Breckenridge AM. Adverse drug reactions: a hospital pharmacy-based reporting scheme. Br J Clin Pharmacol 1989; 28: 113-6.
17. Lee A, Bateman DN, Edwards C, Smith JM. Adverse drug reaction reporting by hospital pharmacists. Pharm J 1993; 251: R19.
18. Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61-8.
19. Bateman DN, Sanders GLS, Rawlins MD. Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol 1992; 34: 421-6.
20. Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 1995; 39: 223-6.